Cardiorenal damages in mice at early phase after intervention induced by angiotensin II, nephrectomy, and salt intake

• Published in: Experimental Animals Vol. 73; no. 1; pp. 11 - 19
• Main Authors: Muromachi, Naoto, Ishida, Junji, Noguchi, Kazuyuki, Akiyama, Tomoki, Maruhashi, Syunsuke, Motomura, Kaori, Usui, Joichi, Yamagata, Kunihiro, Fukamizu, Akiyoshi
• Format: Journal Article
• Language: English
• Published: Japan Japanese Association for Laboratory Animal Science 2024; Japan Science and Technology Agency
• Subjects: Albumin; Albumins; Angiotensin; Angiotensin II; Animal models; animal models for cardiorenal damages: ANS mice; Animals; Blood pressure; Body organs; cardiac hypertrophy and fibrosis; Cardio-Renal Syndrome - drug therapy; cardiorenal damages; Creatinine; Fibrosis; Gelatinase; Global health; Glomerulus; Heart; Homeostasis; Humans; Hypertension; Hypertrophy; Kidney; Kidney diseases; kidney dysfunction with proteinuria; Kidneys; Leukocytes (neutrophilic); Lipocalin; Mice; Nephrectomy; Nephrectomy - adverse effects; Organs; Original; pathogenesis at early phase of cardiorenal damage; Public health; Renal function; Salt loading; Sodium Chloride, Dietary - adverse effects; Tissue; pathogenesis at early phase of cardiorenal damage; cardiac hypertrophy and fibrosis; animal models for cardiorenal damages: ANS mice; cardiorenal damages; kidney dysfunction with proteinuria
• ISSN: 1341-1357; 1881-7122
• DOI: 10.1538/expanim.23-0071

The interconnection of heart performance and kidney function plays an important role for maintaining homeostasis through a variety of physiological crosstalk between these organs. It has been suggested that acute or chronic dysfunction in one organ causes dysregulation in another one, like patients with cardiorenal syndrome. Despite its growing recognition as global health issues, still little is known on pathophysiological evaluation between the two organs. Previously, we established a preclinical murine model with cardiac hypertrophy and fibrosis, and impaired kidney function with renal enlargement and increased urinary albumin levels induced by co-treatment with vasopressor angiotensin II (A), unilateral nephrectomy (N), and salt loading (S) (defined as ANS treatment) for 4 weeks. However, how both tissues, heart and kidney, are initially affected by ANS treatment during the progression of tissue damages remains to be determined. Here, at one week after ANS treatment, we found that cardiac function in ANS-treated mice (ANS mice) are sustained despite hypertrophy. On the other hand, kidney dysfunction is evident in ANS mice, associated with high blood pressure, enlarged glomeruli, increased levels of urinary albumin and urinary neutrophil gelatinase-associated lipocalin, and reduced creatinine clearance. Our results suggest that cardiorenal tissues become damaged at one week after ANS treatment and that ANS mice are useful as a model causing transition from early to late-stage damages of cardiorenal tissues.